Biotage AB (publ) – disclosure notice of substantial holding of shares
Biotage AB (publ) has as of 4 November 2010 bought back an aggregate of 8,848,632 shares under the re-purchase program resolved at the Annual General Meeting with the shareholders on 29 April 2010. The Company`s aggregated holding of own shares corresponds to 10 percent of the total amount of shares and votes in the Company.
The total amount of shares outstanding, including shares held in treasury, amounts to 88,486,320.
The Board of Directors intends to propose the forthcoming Annual General Meeting to resolve that the re-purchased shares shall be cancelled.
Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 12.00 am on 4 November 2010.
Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world’s largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 269 employees and had sales of 394.1 MSEK in 2009. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, firstname.lastname@example.org